Toboroz
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
NCT07725939· 2. fázis· UCB Biopharma SRL· Forrás
Toboroz
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· 4. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
DT-101 in Adults with Major Depressive Disorder
2025-522784-15-00· 2. fázis· Draig Therapeutics Limited· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· 2/3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901· 3. fázis· Kailera· Forrás
Fut, nem toboroz
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· 2. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875· 3. fázis· Kailera· Forrás
Toboroz
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736· 2. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Toboroz
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
2024-512914-16-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· 2. fázis· Intra-Cellular Therapies Inc.· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078· 2. fázis· Upstream Bio Inc.· Forrás
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257· 2. fázis· Pfizer· Forrás
Fut, nem toboroz
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479· 2. fázis· Upstream Bio Inc.· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· 3. fázis· Pharmacosmos A/S· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Meghívásos bevonás
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799· 3. fázis· ACADIA Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD)
2024-513019-29-00· 3. fázis· Mylan Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· 3. fázis· Celltrion Inc.· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Nektar Therapeutics· Forrás
Fut, nem toboroz
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
NCT05222529· 2. fázis· Novartis Pharmaceuticals· Forrás
Showing 50 of 52.